Title |
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
Institution |
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR, HOUSTON, TX
|
Principal Investigator |
Kantarjian, Hagop
|
NCI Program Director |
Steven Nothwehr
|
Cancer Activity |
Translation Research (formerly Organ Systems)
|
Division |
DCTD
|
Funded Amount |
$2,300,000
|
Project Dates |
08/05/2003 - 04/30/2013
|
Fiscal Year |
2012
|
Project Type |
Grant
|
Research Topics w/ Percent Relevance |
Cancer Types w/ Percent Relevance |
Cancer (100.0%)
Chemotherapy (37.0%)
Childhood Cancers (28.0%)
Chronic Myeloproliferative Disorders (51.0%)
Gene Therapy (8.0%)
Genetic Testing (12.0%)
|
Childhood Leukemia (7.0%)
Leukemia (100.0%)
|
Research Type |
Resources and Infrastructure
Resources and Infrastructure Related to Detection, Diagnosis, or Prognosis
Systemic Therapies - Discovery and Development
Systemic Therapies - Clinical Applications
Education and Communication
|
Abstract |
DESCRIPTION (provided by applicant): The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. The SPORE is designed with 5 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia.
Project 1 - Epigenetics and epigenetic therapy in AML
Project 2 - Adoptive Cellular Therapy for Myeloid Leukemia
Project 3 - p53 Activation as Novel Therapeutic Strategy for Acute Myelogenous Leukemia
Project 4 - Incorporating FLT3 inhibitors into AML treatment regimens
Project 5 - Development of Sepacitabine Therapy in Leukemia's
Core and other resources are:
Core A - Administration
Core B - Pathology and Tissue Core
Core C- Biostatistics and Data Management
Development Research Program and Career Development Program.
Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis.
Lay Abstract: This leukemia SPORE integrates clinical and basic investigations to introduce new therapies in leukemia that are aimed at increasing the cure rate in this disease. |